MX9603570A - Metodo y composiciones para incrementar la vida media en suero de agentes farmacologicamente activos. - Google Patents
Metodo y composiciones para incrementar la vida media en suero de agentes farmacologicamente activos.Info
- Publication number
- MX9603570A MX9603570A MX9603570A MX9603570A MX9603570A MX 9603570 A MX9603570 A MX 9603570A MX 9603570 A MX9603570 A MX 9603570A MX 9603570 A MX9603570 A MX 9603570A MX 9603570 A MX9603570 A MX 9603570A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmacologically active
- compositions
- life
- increasing
- serum half
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporcionan las composiciones y los métodos para incrementar la vida en suero de un agente farmacologicamente activo. Las nuevas composiciones son conjugados covalentes del agente farmacologicamente activo seleccionado y un ligando de enlace a transtiretina, tal como ácido tetrayodotiroacético, 2,4-6-triyodofeno,ácido flufenámico o similares.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20038794A | 1994-02-23 | 1994-02-23 | |
PCT/US1995/001815 WO1995022992A2 (en) | 1994-02-23 | 1995-02-13 | Method and compositions for increasing the serum half-life of pharmacologically active agents |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9603570A true MX9603570A (es) | 1997-03-29 |
Family
ID=22741505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9603570A MX9603570A (es) | 1994-02-23 | 1995-02-13 | Metodo y composiciones para incrementar la vida media en suero de agentes farmacologicamente activos. |
Country Status (7)
Country | Link |
---|---|
US (1) | US5714142A (es) |
EP (1) | EP0802798A1 (es) |
JP (1) | JPH09509428A (es) |
AU (1) | AU1843295A (es) |
CA (1) | CA2184002A1 (es) |
MX (1) | MX9603570A (es) |
WO (1) | WO1995022992A2 (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5727798A (en) * | 1996-12-23 | 1998-07-17 | Texas A & M University, The | Anti-amyloidogenic agents |
US6506798B1 (en) | 1997-07-01 | 2003-01-14 | Warner-Lambert Company | 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors |
GB9824632D0 (en) * | 1998-11-10 | 1999-01-06 | Celltech Therapeutics Ltd | Biological compounds |
CA2370653A1 (en) * | 1999-04-26 | 2000-11-02 | Albert Burger | Pharmaceutical compositions of tetrac and methods of use thereof |
US6740680B1 (en) * | 1999-04-26 | 2004-05-25 | Becton Pharma, Inc. | Pharmaceutical compositions to tetrac and methods of use thereof |
US6656730B1 (en) * | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
US6887842B1 (en) * | 1999-11-19 | 2005-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug |
EP1339702A1 (en) | 2000-03-15 | 2003-09-03 | Warner-Lambert Company | 5-amide substituted diarylamines as mek inhibitors |
FI107018B (fi) * | 2000-04-06 | 2001-05-31 | Ipsat Therapies Oy | Dermatologinen käyttö ja valmiste |
EP1399484B1 (en) * | 2001-06-28 | 2010-08-11 | Domantis Limited | Dual-specific ligand and its use |
US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
US6924376B2 (en) | 2002-04-17 | 2005-08-02 | Cytokinetics, Inc. | Compounds, compositions and methods |
US6949538B2 (en) * | 2002-07-17 | 2005-09-27 | Cytokinetics, Inc. | Compounds, compositions, and methods |
JP2005539062A (ja) * | 2002-09-13 | 2005-12-22 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
WO2005042697A2 (en) * | 2003-10-06 | 2005-05-12 | Cytokinetics, Inc. | Compounds, compositions and methods |
US7833979B2 (en) * | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
EP1912946B1 (en) * | 2005-07-20 | 2009-05-27 | Eli Lilly And Company | Pyridine derivatives as dipeptedyl peptidase inhibitors |
WO2007015807A1 (en) * | 2005-07-20 | 2007-02-08 | Eli Lilly And Company | Phenyl compounds |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
US8168592B2 (en) * | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
CA2667678A1 (en) * | 2006-10-25 | 2008-07-24 | Amgen Inc. | Toxin peptide therapeutic agents |
EP2162540A2 (en) | 2007-05-22 | 2010-03-17 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
CN102015606B (zh) | 2007-06-08 | 2015-02-04 | 满康德股份有限公司 | IRE-1α抑制剂 |
US20090131380A1 (en) * | 2007-11-16 | 2009-05-21 | Pekka Heino | Novel pharmaceutical composition for topical treatment of skin psoriasis and the treatment method thereof |
MX347291B (es) | 2009-03-20 | 2017-04-17 | Amgen Inc | Inmunoglobulinas portadoras y usos de las mismas. |
EA201370076A1 (ru) | 2010-09-22 | 2013-08-30 | Амген Инк. | Иммуноглобулины-переносчики и их применение |
CA2828405A1 (en) | 2011-02-28 | 2012-09-07 | Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale | Apoptosis-inducing molecules and uses therefor |
US9340590B2 (en) | 2011-03-16 | 2016-05-17 | Amgen Inc. | Potent and selective inhibitors of NaV1.3 and NaV1.7 |
CA3062003C (en) | 2012-05-17 | 2022-01-11 | Extend Biosciences, Inc. | Vitamin d as a targeting group for therapeutic peptides |
EP2908849B1 (en) * | 2012-08-31 | 2019-04-17 | Board Of Regents, The University Of Texas System | A method to improve pharmacokinetics of drugs |
US9029342B2 (en) | 2012-09-17 | 2015-05-12 | Board Of Regents Of The University Of Texas System | Compositions of matter that reduce pain, shock, and inflammation by blocking linoleic acid metabolites and uses thereof |
WO2014099984A1 (en) | 2012-12-20 | 2014-06-26 | Amgen Inc. | Apj receptor agonists and uses thereof |
WO2014165277A2 (en) | 2013-03-12 | 2014-10-09 | Amgen Inc. | POTENT AND SELECTIVE INHIBITORS OF Nav1.7 |
CA2951391C (en) | 2014-06-10 | 2021-11-02 | Amgen Inc. | Apelin polypeptides |
EP3179857B1 (en) | 2014-08-14 | 2021-09-08 | Mamoun M. Alhamadsheh | Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
EP3220961B1 (en) | 2014-10-22 | 2023-07-05 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
US20190382462A1 (en) | 2017-01-13 | 2019-12-19 | Pietro P. Sanna | Methods and compositions for treating hpa hyperactivity |
US20210346513A1 (en) | 2017-08-04 | 2021-11-11 | Amgen Inc. | Method of conjugation of cys-mabs |
FR3113904B1 (fr) | 2020-09-08 | 2022-08-12 | Innoverda | Procédé de synthèse du 3,5-diiodo-4-hydroxy benzylalcool |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4410633A (en) * | 1980-09-25 | 1983-10-18 | Corning Glass Works | Method for the measurement of free thyroxine or 3,5,3'-triiodothyronine in a liquid sample |
US5068227A (en) * | 1989-01-18 | 1991-11-26 | Cyclex, Inc. | Cyclodextrins as carriers |
SE509359C2 (sv) * | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
US5273885A (en) * | 1992-07-31 | 1993-12-28 | Syntex (U.S.A.) Inc. | Conjugates of monophenyl thyroid analogs useful in assays |
-
1995
- 1995-02-13 CA CA002184002A patent/CA2184002A1/en not_active Abandoned
- 1995-02-13 AU AU18432/95A patent/AU1843295A/en not_active Abandoned
- 1995-02-13 EP EP95910249A patent/EP0802798A1/en not_active Withdrawn
- 1995-02-13 JP JP7522373A patent/JPH09509428A/ja active Pending
- 1995-02-13 MX MX9603570A patent/MX9603570A/es unknown
- 1995-02-13 WO PCT/US1995/001815 patent/WO1995022992A2/en not_active Application Discontinuation
-
1996
- 1996-06-13 US US08/664,372 patent/US5714142A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JPH09509428A (ja) | 1997-09-22 |
EP0802798A1 (en) | 1997-10-29 |
CA2184002A1 (en) | 1995-08-31 |
US5714142A (en) | 1998-02-03 |
WO1995022992A2 (en) | 1995-08-31 |
WO1995022992A8 (en) | 2002-02-14 |
AU1843295A (en) | 1995-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9603570A (es) | Metodo y composiciones para incrementar la vida media en suero de agentes farmacologicamente activos. | |
CA2234282A1 (en) | Drug-resin complexes stabilized by chelating agents | |
IL106665A0 (en) | Powder compositions for inhalation | |
ID28003A (id) | Turunan-turunan adamantana | |
ZA91353B (en) | Pharmaceutical and cosmetic compositions | |
IL124411A0 (en) | Lipopolyamines as transfection agents and pharmaceutical uses thereof | |
CA2229077A1 (en) | Lipid metabolism improving agent | |
BG101139A (en) | Heteroatoms-containing cyclopentanopyridyloxazolidinons | |
HK1017995A1 (en) | Compounds and compositions for delivering active agents. | |
CA2186260A1 (en) | Composition comprising morphine, polypyrrolidone and a polyalkyleneoxide | |
PL319833A1 (en) | Compounds and composition for carrying active media | |
IL115790A0 (en) | Pharmaceutical compositions containing boronic ester and acid compounds and methods for the preparation thereof | |
CA2338358A1 (en) | Compounds and compositions for delivering active agents | |
SE9704546D0 (sv) | Novel compounds | |
AU5162796A (en) | Novel peptide derivatives | |
MY131774A (en) | Coated pesticidal agents, processes for their preparation and compositions containing them | |
AU689817B2 (en) | Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins, and pharmaceutical formulations and methods thereof | |
IL109720A (en) | N-alkylthio polyamine derivatives and radioprotective compositions containing them | |
NZ236050A (en) | Water soluble conjugate of a polymyxin and a carrier | |
AU633867B2 (en) | Delivery of cytotoxic agents | |
BG100863A (en) | Fibrin-specifil antibody and its use as an antithrombotic agent | |
MY132057A (en) | Quinoxalinones, a process for their preparation and their use | |
GR3031118T3 (en) | Novel seco-D steroids active in the cardiovascular system and pharmaceutical compositions containing same | |
IL114488A0 (en) | Amino acid-derived diaminopropanols | |
FI933506A (fi) | Bisyklopolyatsamakrosyklokarboksyylihappokomplekseja, niiden konjugaatteja, menetelmä niiden valmistamiseksi ja käyttö varjoaineina |